Key Points
Nov 17 (Reuters) - The U.S. health regulator's advisers said on Friday that data on Merck's (MRK.N) chronic cough drug gefapixant does not provide sufficient evidence to prove its clinical benefit for patients...
The FDA panel voted 12 to 1 against the data submitted by Merck, which showed a small reduction in cough frequency and side effects such as loss of taste in patients who received the treatment...
Merck's drug is up against GSK-owned camlipixant, which is in late-stage development for the treatment of chronic cough with anticipated regulatory approval and launch in 2026...
